Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment - Wikidata - wikimedia - TriplyDB

Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment

Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment

http://www.wikidata.org/entity/Q35227986

about

Tumor Heterogeneity in Hepatocellular Carcinoma: Facing the Challenges Evaluation and consequences of heterogeneity in the circulating tumor cell compartment Notes for developing a molecular test for the full characterization of circulating tumor cells Detection of Circulating Tumor Cells in Non-Small Cell Lung Cancer Current Status of CTCs as Liquid Biopsy in Lung Cancer and Future Directions Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer Microfluidic enrichment for the single cell analysis of circulating tumor cells.Recent advances in the biology of human circulating tumour cells and metastasis Liquid biopsy based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoring Circulating tumor cells versus circulating tumor DNA in lung cancer-which one will win?Emerging platforms using liquid biopsy to detect EGFR mutations in lung cancer Circulating tumor cells in early stage lung adenocarcinoma: a case series report and literature review Cancer gene panel analysis of cultured circulating tumor cells and primary tumor tissue from patients with breast cancer.Next-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification.Comparison of droplet digital PCR and conventional quantitative PCR for measuring EGFR gene mutation.Isolation and Characterization of Circulating Tumor Cells in Squamous Cell Carcinoma of the Lung Using a Non-EpCAM-Based Capture Method.Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses.Sensitive cytometry based system for enumeration, capture and analysis of gene mutations of circulating tumor cells The potential for liquid biopsies in the precision medical treatment of breast cancer.Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma.Technological advances in precision medicine and drug development.Is it feasible to detect epidermal growth factor receptor mutations in circulating tumor cells in nonsmall cell lung cancer?: A meta-analysis.Vertical Magnetic Separation of Circulating Tumor Cells for Somatic Genomic-Alteration Analysis in Lung Cancer Patients.Methods: for studying pharmacogenetic profiles of combination chemotherapeutic drugs.Advances in clinical next-generation sequencing: target enrichment and sequencing technologies.Circulating Tumor Cells: Back to the Future Liquid Biopsy and its Potential for Management of Hepatocellular Carcinoma.Liquid Biopsy in Non-Small Cell Lung Cancer.The Emerging Role of "Liquid Biopsies," Circulating Tumor Cells, and Circulating Cell-Free Tumor DNA in Lung Cancer Diagnosis and Identification of Resistance Mutations.Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line Molecular analysis of peripheral non-squamous non-small cell lung cancer sampled by radial EBUS.Challenges and unanswered questions for the next decade of circulating tumour cell research in lung cancer.Biology and clinical significance of circulating tumor cell subpopulations in lung cancer Biophysical technologies for understanding circulating tumor cell biology and metastasis.Routine clinical use of circulating tumor cells for diagnosis of mutations and chromosomal rearrangements in non-small cell lung cancer-ready for prime-time?Survival of metastatic melanoma patients after dendritic cell vaccination correlates with expression of leukocyte phosphatidylethanolamine-binding protein 1/Raf kinase inhibitory protein.Non-invasive diagnostic platforms in management of non-small cell lung cancer: opportunities and challenges.Critical issues in the clinical application of liquid biopsy in non-small cell lung cancer.Molecular characterization and prognostic significance of circulating tumor cells in patients with non-small cell lung cancer.Blood-based tumor biomarkers in lung cancer for detection and treatment.

P2860

Q26744100-664C95BC-9825-4908-8989-AF0FCD51E78B Q26765357-CD2B815F-30F2-4DDC-9E61-D8F5E5130CA5 Q26778913-2C7553C2-2995-44CE-BE35-07B2951D34E9 Q26781088-88F24F71-FDAF-4627-A315-1B717BE12702 Q26781333-0A453488-A6F0-4F54-8AB1-4ED840B425FF Q26801357-9EF9B20B-409B-42ED-B608-50E107BFC14F Q27340255-0F035AFB-89D3-4C93-BB3F-0BCF017884C6 Q28070120-A5CAB05B-D419-4124-AC9A-87DE25CE8644 Q28076191-4FF7F614-472B-4564-AB95-69995B29BC65 Q28077340-013E6798-029D-41E4-92D1-98B924A27FD9 Q28082499-7FB726AB-D709-44C3-9C95-ED54C5234307 Q33618596-0946F3D5-B4BB-4829-95D7-CF219305D8DA Q33751043-6C5CBC5F-3177-4EAD-9268-A61A622A8DAC Q34550417-1454553D-2AEE-4693-85D3-22F0B4FCF8F9 Q35159562-41360693-82FA-4627-B9B0-F27127FA3E04 Q35842078-F80918AE-006A-43D3-8D07-03D44635ADD6 Q36643142-4E4188B1-A4CD-430D-80A7-E175E3ACFBA4 Q36746316-19ADDE2B-FFAF-452F-9C28-337B40AE82DF Q36849660-2077E42C-197E-4B1D-8F03-F99887EB8E75 Q37051546-5388255E-19F5-48E2-AE9D-02A2F32EFFDE Q37244501-FEC08F59-7861-4510-8584-331A0067C9FF Q37468081-641DDE3B-0585-4F04-A0A6-1E36F291D59D Q38408223-A61AD1A9-8A51-4EA6-9D86-E7D107AA8B3F Q38513661-C36AA567-01C7-4E98-8F71-0F76FC75EE70 Q38672934-C8F3FC25-97EC-4597-9C33-0EB2EC976EA4 Q38765748-7D230EE4-EBC6-46D0-A7EC-377B99A9850C Q38770935-224F5791-E6E3-45F8-A21D-7116374FB142 Q39076207-9E74FA22-4421-430D-89B9-7CD777F6D83C Q39097813-5578B435-6767-4BA0-BCF6-F6F161B15CF0 Q39114552-341914F8-F038-4898-AE12-EA61F6FAA9C5 Q39835396-632CF0C7-82BD-444D-B202-48F42781D5D8 Q41605016-38AB0039-F7BF-42A8-8C4C-F1DBD7CC6E5E Q41605032-11D56406-5593-47BE-929F-7B6B5146C762 Q41605039-8D2E8FA4-B23A-4343-9D54-A86939758A65 Q41605055-97C7AE9A-A7FB-4C07-A086-0EAB3CAA5048 Q41976096-3E265F5C-FA3C-4A96-AFE1-6A66568D4C23 Q45891469-DC382028-B782-413E-B656-6667B9450753 Q47104064-486CBC5F-642A-42F5-87F6-0566DA926A3F Q47110464-004550D7-8E4A-488B-9DCF-A136BF9F9AA6 Q47126156-2BBF1D56-6F6E-45E7-8B11-2011FA607C9E

P2860

Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment

http://www.wikidata.org/entity/Q35227986

description

2014 nî lūn-bûn

@nan

2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Assessment of EGFR mutations i ...... me liquid biopsy for treatment

@ast

Assessment of EGFR mutations i ...... me liquid biopsy for treatment

@en

type

label

Assessment of EGFR mutations i ...... me liquid biopsy for treatment

@ast

Assessment of EGFR mutations i ...... me liquid biopsy for treatment

@en

prefLabel

Assessment of EGFR mutations i ...... me liquid biopsy for treatment

@ast

Assessment of EGFR mutations i ...... me liquid biopsy for treatment

@en

P1433

Q35227986-C10A425D-8532-4663-AEED-81BACC0A5C32

P1476

Q35227986-C8F75D70-9835-495C-BB47-D450833DA1AA

P2093

Q35227986-1D27EAF6-1EA1-47FE-8F86-F1D3F8BD5E34

Q35227986-336F8B86-C5E7-4769-86A8-D752EF0335B3

Q35227986-4DAACABA-C758-4D3B-A86D-E359E1C489DC

Q35227986-795D9C73-10FD-4CFE-9EC1-0A29E7D7BDEE

Q35227986-81BF8E42-CE0F-4740-882D-6752229A1B9B

Q35227986-AD07B696-A71E-4350-9AB7-2A8C9EED862F

Q35227986-B2C6F00C-12B2-4D7C-9C06-A2B201030689

Q35227986-B612F435-A0B6-4E6B-83D9-BAAD71EFA698

Q35227986-BBF2EACB-7B9A-4D44-8C6E-9156836AEB10

Q35227986-BFAF6D8A-8C93-4C02-9B21-E301A11967D6

P2860

Q35227986-039046B7-92D8-48CC-83EA-AC4ABF9B6B6F

Q35227986-03F0DA0A-C74E-41EE-A1A1-344D3E2D67D2

Q35227986-054CF32D-9045-4956-9F96-A7D2C1BFAD2E

Q35227986-06DC3086-0AB5-4E28-A184-CD2FE739B4CC

Q35227986-07C67E72-725C-4E2E-A44F-3102B176DFEA

Q35227986-38133B17-082F-452F-A966-05023273F982

Q35227986-3CCE5320-4B00-4ACF-A072-7356AC2D5149

Q35227986-4162AA03-A04D-4C23-B972-892DD53416C8

Q35227986-42812E61-364B-468B-95DF-D7E9394B869F

Q35227986-439709DB-48AF-48CD-9C1D-D2B35B9D2EC4

P304

Q35227986-83166F97-1CA1-4B39-8E8B-E18BB0831B51

P31

Q35227986-BA78FDC7-8BF6-4414-96E3-FA520A32EB96

P356

Q35227986-E7C7B1B8-B12C-4D8E-A8DC-25CC0C044E97

P407

Q35227986-BEB4E5D1-FB55-4741-9E42-5FFA9A3A8A2D

P433

Q35227986-B1BB4931-2A5E-496F-A05C-EE6C16AA8366

P478

Q35227986-4A97FEFC-704B-447C-985D-2DEB584F89D3

P50

Q35227986-D28D6589-432B-4A97-B9A2-9D1318DA1332

P577

Q35227986-66446823-CFA3-41D9-AA7A-002C7B3429C2

P5875

Q35227986-C124B4BE-D846-4322-9155-448D4D97822A

P698

Q35227986-FF86A4C5-5CC5-493C-974D-64CE89ED3E2F

P932

Q35227986-5470C6A2-B842-4591-98D2-53798D3708A3

P356

JOURNAL.PONE.0103883

P1433

P1476

Assessment of EGFR mutations i ...... me liquid biopsy for treatment

@en

P2093

Alba Ariela Brandes

http://www.w3.org/2001/XMLSchema#string

Antonio Chella

http://www.w3.org/2001/XMLSchema#string

Antonio Marchetti

http://www.w3.org/2001/XMLSchema#string

Fiamma Buttitta

http://www.w3.org/2001/XMLSchema#string

Franco Cuccurullo

http://www.w3.org/2001/XMLSchema#string

Giampaolo Filice

http://www.w3.org/2001/XMLSchema#string

Irene Centi

http://www.w3.org/2001/XMLSchema#string

Lara Felicioni

http://www.w3.org/2001/XMLSchema#string

Lucio Crinò

http://www.w3.org/2001/XMLSchema#string

Maela Del Grammastro

http://www.w3.org/2001/XMLSchema#string

P2860

Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients with Metastatic Breast Colorectal and Prostate Cancer

Isolation of rare circulating tumour cells in cancer patients by microchip technology

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Next-generation DNA sequencing methods

Molecular biomarker analyses using circulating tumor cells

Detection of mutations in EGFR in circulating lung-cancer cells

Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer

Isolation of circulating tumor cells using a microvortex-generating herringbone-chip.

Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology.

Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer.

P304

e103883

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0103883

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Armando Santoro

P577

2014-08-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

264902810

http://www.w3.org/2001/XMLSchema#string

P698

25137181

http://www.w3.org/2001/XMLSchema#string

P932

4138040

http://www.w3.org/2001/XMLSchema#string